


A Novel Antihypertensive Agent: 1,2,3,5-Tetrahydroimidazo[2,1-b]quinazoline

In the course of a broad investigation of 'amidines'¹ as potential antihypertensive agents, the title compound (II) was synthesized by the lithium aluminum hydride reduction of lactam I². The hydrochloride of II has mp 251–253°C; analysis for C₁₀H₁₁N₃·HCl: Calcd: C, 57.28; H, 5.77; found: C, 56.89; H, 6.00; $\lambda_{\text{max}}^{\text{EtOH(KOH)}}$ 278 nm (log ϵ = 4.09).



This compound is a potent antihypertensive agent which is orally effective in rats, dogs, cats, and rabbits. It lowered the blood pressure significantly in the meta-corticoid hypertensive rat³ (5 mg/kg p.o.), in the unanesthetized neurogenic hypertensive dog⁴ (2.5 mg/kg p.o.), and in the normotensive dog (2.5 mg/kg p.o.) without precipitating reflex tachycardia at these doses. The duration of action was sustained up to 48 h. No tolerance developed in a chronic study of 3 weeks duration. Preliminary studies of its mode of hypotensive action seem to exclude a central mechanism. Its peripheral action appears

complex, although α -adrenergic blockade has been established as one of the components. Catecholamine depletion was demonstrated by a moderate reduction of norepinephrine level in the rat's heart. Mechanisms involving direct vascular dilation or ganglion blockade were excluded. The possible occurrence of orthostatic hypotension associated with the α -blockade activity of this agent was not observed in the rabbit tilt test⁵; this is in contrast to the result of a parallel study with phenoxybenzamine. The LD₅₀ (p.o.) of II (HCl) for rats was found to be 900 mg/kg.

Full reports of the chemistry and pharmacology of this new agent and analogs will be presented in the near future.

Zusammenfassung. 1, 2, 3, 5-Tetrahydroimidazo(2,1-b)-chinazolin wurde als neuer Typ eines bei Tieren gut wirkenden Hypotensivums erkannt. Bei α -blockierender Komponente wurde keine orthostatische Hypotonie festgestellt.

B. LOEV, T. JEN and R. A. McLEAN

Research Division, Smith Kline and French Laboratories,
1500 Spring Garden Street, Philadelphia
(Pennsylvania 19101, USA), 2 March 1971.

¹ Manuscripts in preparation.

² E. ZIEGLER, W. STEIGER and TH. KAPPE, *Mh. Chem.* **99**, 1499 (1968). – R. J. GROUT and M. W. PARTRIDGE, *J. chem. Soc.* **1960**, 3551.

³ D. M. GREEN, F. J. SAUNDERS, N. WAHLGREN and R. L. CRAIG, *Am. J. Physiol.* **170**, 94 (1952).

⁴ K. S. GRIMSON, *Archs Surg., Lond.* **43**, 284 (1941).

⁵ J. PARRA and H. VIDRIO, *Archs int. Pharmacodyn. Théor.* **181**, 353 (1969).

The Synthesis of Toxicarol Isoflavone

Toxicarol isoflavone, C₂₃H₂₂O₇, was isolated from the root of *Derris malaccensis* along with rotenoids (rotenone, toxicarol (I) etc.) by HARPER¹. Its structure was identified as 2'', 2''-dimethylpyrano(6'', 5'':7,8)-5-hydroxy-2', 4', 5'-trimethoxyisoflavone (II) on the basis of NMR spectral evidence². II is very likely to be related biogenetically to I. The present paper will describe the synthesis of II confirming the proposed structure.

By a modified Hoesch reaction, 2,2-dimethyl-5-hydroxy-7-methoxychroman³ was condensed with 2,4,5-trimethoxy-phenylacetonitrile⁴ in the presence of anhydrous aluminum chloride to give the corresponding desoxybenzoins (III, mp 177–178°, NMR⁵ 14.17_s (Phenol [intramolecular hydrogen bonding]) and IV, mp 152–154°, NMR 6.8_{bs} (Phenol [other phenol])). Treatment of III with ethyl formate in the presence of sodium gave the dihydropyranoisoflavone (V, mp 188–189.5°, IR 1663, 1641 cm⁻¹ (Nujol), UV $\lambda_{\text{max}}^{\text{EtOH}}$ nm (log ϵ): 259(4.50), 295(4.17), NMR 1.87_t (J = 7 Hz), 2.80_s (J = 7 Hz) (–CH₂–CH₂–), 7.86_s (C₆–H). Found: C, 67.51; H, 5.86. C₂₄H₂₈O₇ requires: C, 67.59; H, 6.15%). V was dehydrogenated with DDQ to give toxicarol isoflavone methyl ether (VI, mp 179–181°, IR 1665, 1641 cm⁻¹ (Nujol); UV $\lambda_{\text{max}}^{\text{EtOH}}$ nm (log ϵ): 264 (4.58), 293_{sh}(4.08), NMR 1.48_s (6H) ((CH₃)₂C <), 3.72_s,

3.83_s, 3.90_s(6H) (CH₃O), 5.57_d (J = 10 Hz) (C₃''–H), 6.31_s (C₆–H), 6.59_s (C₃–H), 6.74_d (J = 10 Hz) (C₄–H), 6.97_s (C₆–H), 7.80_s (C₂–H). Found: C, 66.71; H, 5.89. C₂₃H₂₂O₇·1/2H₂O requires: C, 66.50; H, 5.81%) (lit.¹ mp 178°). The partial demethylation of VI with anhydrous aluminum chloride in acetonitrile gave the desired isoflavone (II, mp 220–220.5°, IR 1656 cm⁻¹, UV $\lambda_{\text{max}}^{\text{EtOH}}$ nm (log ϵ): 269(4.62), NMR 1.47_s(6H) ((CH₃)₂C <), 3.79_s, 3.86_s, 3.92_s (CH₃O), 5.58_d (J = 10 Hz) (C₃''–H), 6.29_s (C₆–H), 6.65_s (C₃–H), 6.72_d (J = 10) (C₄–H), 6.92_s (C₆–H), 7.92_s (C₂–H), 12.92_s (OH). Found: C, 67.50; H, 5.42. C₂₃H₂₂O₇ requires: C, 67.31; H, 5.41%) (lit.¹ mp 219°), which was easily converted into

¹ S. H. HARPER, *J. chem. Soc.* **1940**, 1178.

² S. H. HARPER and W. G. E. UNDERWOOD, *J. chem. Soc.* **1965**, 4203.

³ S. N. GEORGE and A. ROBERTSON, *J. chem. Soc.* **1937**, 1535. – A. P. JOHNSON and A. PELTER, *J. chem. Soc.* **1966**, 606.

⁴ J. HARLEY-MASON and A. H. JACKSON, *J. chem. Soc.* **1954**, 1165.

⁵ The NMR-spectra were measured with a Hitachi R-20 (60 MHz) spectrometer, using tetramethylsilane as the internal standard (δ -value in CDCl₃; s, singlet; bs, broad singlet; d, doublet; t, triplet).